List of Excipients in Branded Drug BROMDAY

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Unit Dose Services	BROMDAY	bromfenac	50436-6301	BENZALKONIUM CHLORIDE
Unit Dose Services	BROMDAY	bromfenac	50436-6301	BORIC ACID
Unit Dose Services	BROMDAY	bromfenac	50436-6301	EDETATE DISODIUM
Unit Dose Services	BROMDAY	bromfenac	50436-6301	POLYSORBATE 80
Unit Dose Services	BROMDAY	bromfenac	50436-6301	POVIDONES
Unit Dose Services	BROMDAY	bromfenac	50436-6301	SODIUM BORATE
Unit Dose Services	BROMDAY	bromfenac	50436-6301	SODIUM HYDROXIDE

BROMDAY Excipient Strategy and Commercial Opportunities in Ophthalmic Bromfenac

Last updated: August 24, 2026

BROMDAY is a once-daily bromfenac sodium ophthalmic solution containing 0.09% active ingredient. Its commercial differentiation came from dosing convenience and ocular tolerability rather than from a novel active pharmaceutical ingredient. The formulation uses a conventional preserved aqueous vehicle with borate buffering, chelation, wetting, viscosity, and oxidation-control functions. The strongest commercial opportunities are generic substitution, preservative-free reformulation, multidose delivery, improved postoperative adherence, and differentiated bromfenac products that reduce ocular-surface burden.

What is BROMDAY and how does its formulation work?

BROMDAY is a topical nonsteroidal anti-inflammatory drug, or NSAID, indicated for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery. The product contains bromfenac sodium equivalent to bromfenac 0.09% in an ophthalmic solution administered once daily.[1]

Bromfenac inhibits cyclooxygenase-mediated prostaglandin synthesis. In ophthalmic surgery, this mechanism supports control of postoperative inflammation, pain, and related ocular symptoms. BROMDAY competes in a market that includes ketorolac, nepafenac, diclofenac, and other topical ophthalmic NSAIDs.

The commercial value of BROMDAY rests on four formulation attributes:

1. A relatively concentrated bromfenac formulation.
2. Once-daily dosing.
3. A sterile aqueous solution that avoids the manufacturing complexity of a suspension.
4. A preserved multidose container suitable for conventional pharmacy distribution.

BROMDAY was developed as a once-daily successor to twice-daily bromfenac ophthalmic products. Its formulation strategy was intended to maintain ocular exposure while reducing the number of postoperative administrations.

What excipients are used in BROMDAY?

BROMDAY contains a multifunctional excipient system rather than a single proprietary delivery technology. The product label identifies the following inactive ingredients:[1]

Excipient or formulation component	Primary function
Benzalkonium chloride	Antimicrobial preservative
Boric acid	Buffering and tonicity adjustment
Edetate disodium	Chelating agent; supports preservative performance and chemical stability
Povidone	Wetting, lubricity, and viscosity modification
Sodium borate decahydrate	Borate buffer system
Sodium sulfite	Antioxidant or oxidation-control excipient
Tyloxapol	Surfactant and wetting agent
Sodium hydroxide	pH adjustment
Water for injection	Vehicle

The formulation is an aqueous, buffered, preserved solution. No suspension technology, oil phase, cyclodextrin complex, liposomal carrier, or polymeric nanoparticle system is identified in the BROMDAY labeling.

How does each BROMDAY excipient create commercial value?

Benzalkonium chloride, commonly abbreviated BAK, enables multidose packaging by controlling microbial contamination during use. It is commercially efficient because it supports conventional dropper-bottle formats and does not require a specialized preservative-free container.

Its disadvantage is ocular-surface exposure. Repeated use of BAK-containing ophthalmic products can contribute to epithelial toxicity, tear-film disruption, and irritation, particularly in patients with pre-existing dry eye or frequent exposure to topical medications. A preservative-free bromfenac product could therefore command a premium if it demonstrates equivalent sterility, stability, usability, and postoperative outcomes.

Boric acid and sodium borate create the buffer system. Buffer selection affects pH stability, comfort on instillation, bromfenac solubility, and compatibility with the container closure. Borate systems are common in ophthalmic products because they can provide acceptable buffering capacity at relatively low excipient concentrations.

Edetate disodium binds trace metal ions that can catalyze oxidation and can improve preservative effectiveness. It is a low-cost excipient with a high formulation value because small amounts can improve robustness without materially increasing product cost.

Povidone improves wetting and lubrication. It can reduce the perception of dryness or foreign-body sensation and can support uniform drop formation. Its concentration must be controlled because viscosity affects drop size, dispensing behavior, and residual ocular residence time.

Tyloxapol is a nonionic surfactant. It assists wetting and can improve the uniform distribution of bromfenac in the aqueous vehicle. It also affects interfacial behavior during filling, storage, and drop dispensing. Surfactant selection is a potential area for differentiated formulation work, particularly where a company seeks to reduce irritation or improve drug delivery without increasing viscosity.

Sodium sulfite provides oxidation control. Sulfite selection creates a tradeoff between chemical stability and tolerability. Oxidation-control systems must be assessed against bromfenac degradation pathways, dissolved oxygen, light exposure, container permeability, and manufacturing hold times.

What formulation attributes are protected by BROMDAY-related intellectual property?

The core bromfenac molecule is not the primary source of current commercial protection. For products in this category, relevant intellectual property can involve:

• Concentration and dosing frequency.
• Bromfenac salt selection.
• pH and buffer composition.
• Surfactant and wetting-agent combinations.
• Preservative concentration.
• Antioxidant systems.
• Container and closure configuration.
• Methods for treating postoperative inflammation or pain.
• Manufacturing processes that improve stability or sterility assurance.

A generic applicant may avoid infringement by using different excipient concentrations, a different buffer, a different preservative, or a different container system while maintaining the same active ingredient and strength. That makes formulation patents more difficult to enforce when claims are narrow or when several alternative excipient combinations provide comparable performance.

BROMDAY is associated with U.S. FDA New Drug Application 022141. FDA product databases and the Orange Book should be used to determine the current listing status of the NDA, patents, and regulatory exclusivity.[2] BROMDAY-specific patent conclusions should not be inferred from patents covering other bromfenac products such as XIBROM, PROLENSA, or BROMSITE. These products differ in strength, dosing, formulation, or development sponsor.

When did BROMDAY lose exclusivity?

BROMDAY received FDA approval in 2009 as a once-daily bromfenac ophthalmic product.[1] Its original commercial exclusivity period has expired. Any current market protection must therefore be evaluated through remaining patents, regulatory status, manufacturing barriers, brand recognition, and differentiated formulation claims.

The relevant competitive distinction is between:

Product type	Primary commercial barrier
Generic bromfenac 0.09% solution	ANDA approval, bioequivalence, CMC quality, and pharmacy substitution
Preservative-free bromfenac	Container system, sterility assurance, stability, and clinical differentiation
Bromfenac suspension or enhanced-delivery product	Particle control, dose uniformity, resuspendability, and ophthalmic tolerability
Combination product	Method-of-use claims, clinical development, and regulatory approval
Branded BROMDAY successor	Physician familiarity, supply reliability, and payer positioning

FDA approval of a generic ophthalmic solution does not require the generic to copy every inactive ingredient. FDA generally evaluates whether the proposed product is pharmaceutically equivalent and therapeutically equivalent under the applicable ANDA pathway, subject to formulation and safety requirements.[3]

What generic entry risks exist for BROMDAY?

Generic entry risk is high for a conventional ophthalmic solution after active-ingredient and regulatory exclusivities expire. The main risks are price compression, pharmacy substitution, formulary displacement, and loss of surgical-center purchasing share.

The most important generic-development issues are:

Bioequivalence and product quality

Topical ophthalmic solutions must demonstrate the required pharmaceutical equivalence, including strength, dosage form, route of administration, and quality attributes. Depending on the product and FDA pathway, applicants may need to address comparative physicochemical properties, pH, osmolality, viscosity, drop size, drug content, impurities, preservative content, and microbial quality.

Excipient differences

An ANDA applicant may use different inactive ingredients if the formulation remains acceptable from a safety, performance, and regulatory perspective. Differences in surfactant, preservative, buffer, or antioxidant can create a commercial distinction but may also introduce new irritation, stability, or container-compatibility risks.

Container closure

Ophthalmic products require tight control of extractables, leachables, oxygen ingress, light transmission, closure integrity, and dispensing performance. A generic product that matches the active ingredient but has a less reliable bottle or inconsistent drop size can lose physician and pharmacy confidence.

Manufacturing scale-up

The formulation is technically straightforward compared with an injectable or biologic, but sterile ophthalmic manufacturing remains a meaningful barrier. Companies need validated sterilization or aseptic processing, low bioburden controls, filling accuracy, preservative uniformity, and stability data.

How strong is the BROMDAY patent estate?

The practical strength of a BROMDAY patent estate depends on the scope and remaining term of formulation, method-of-use, and delivery claims. A broad composition claim covering bromfenac 0.09% in an ophthalmic solution would have greater blocking value than a narrow claim limited to a specific buffer ratio or excipient concentration.

A commercial assessment should separate four categories:

IP category	Likely relevance
Active-ingredient patents	Limited for an older bromfenac product
Formulation patents	Potentially relevant to pH, excipients, stability, or concentration
Method-of-use patents	Potential relevance to postoperative inflammation and dosing
Device and packaging patents	Relevant to preservative-free or specialized multidose systems

Method-of-use patents may have limited practical value when physicians can prescribe a generic product for the same surgical indication under an alternative label or treatment rationale. Formulation patents are more valuable when they cover a measurable product attribute that competitors cannot readily design around.

The strongest modern strategy would combine formulation claims with container-closure claims, stability data, and clinical evidence showing reduced irritation or improved adherence.

What preservative-free opportunities exist for bromfenac?

Preservative-free bromfenac is the clearest excipient-led opportunity. The product would remove BAK and require a replacement delivery and sterility strategy.

Potential platforms include:

• Unit-dose vials.
• Preservative-free multidose bottles with one-way valves.
• Metered-dose pumps.
• Blow-fill-seal containers.
• Oxygen-limiting packaging.
• Low-surface-area closure systems.

Unit-dose packaging has the simplest microbial-control concept but increases packaging cost, manufacturing volume, shipping weight, and patient handling requirements. Preservative-free multidose systems improve convenience but require stronger container-closure and microbial ingress controls.

The commercial target is patients with dry eye, ocular-surface disease, glaucoma therapy, repeated postoperative dosing, or known sensitivity to preserved products. The product would also fit ophthalmology practices seeking to reduce total preservative exposure across postoperative regimens.

A preservative-free formulation must preserve bromfenac stability without relying on BAK or the existing sulfite system. The development program would need to assess antioxidant selection, oxygen exposure, photostability, container adsorption, drop consistency, and microbial integrity throughout the labeled in-use period.

How does BROMDAY compare with PROLENSA, XIBROM, and BROMSITE?

Product	Bromfenac strength	Typical dosing distinction	Commercial implication
XIBROM	0.09%	Twice daily	Earlier bromfenac product; higher administration burden
BROMDAY	0.09%	Once daily	Convenience-led positioning
PROLENSA	0.07%	Once daily	Lower-strength branded formulation with separate product positioning
BROMSITE	0.075%	Typically once daily in postoperative use	Differentiated bromfenac formulation and commercial brand

These products should not be treated as interchangeable from an intellectual-property perspective. Each may have separate patents, labeling, formulation claims, regulatory history, and settlement arrangements. Generic competition against one product does not automatically establish the regulatory or litigation position of another.

BROMDAY's key disadvantage is that once-daily dosing alone is no longer a durable differentiator. A new product needs an additional value proposition, such as preservative-free delivery, lower irritation, improved ocular retention, lower bottle waste, or a combination with another postoperative therapy.

Which companies can challenge the BROMDAY market?

The competitive field includes generic ophthalmic manufacturers, branded ophthalmology companies, contract development and manufacturing organizations, and suppliers with proprietary preservative-free delivery systems.

Generic manufacturers can compete through low-cost bromfenac 0.09% solutions. Branded ophthalmology companies can compete through improved formulation, surgical-channel relationships, or bundled postoperative products. Device companies can capture value by licensing multidose preservative-free packaging to an established ophthalmic manufacturer.

The most attractive licensing structure would pair:

1. A validated bromfenac formulation.
2. A proprietary preservative-free container.
3. Existing sterile ophthalmic manufacturing capacity.
4. A commercial partner with ophthalmology distribution.

This model can reduce development time and avoid building a complete ophthalmic sales infrastructure.

What is the FDA and Orange Book status of BROMDAY?

BROMDAY was approved through an FDA NDA for bromfenac sodium ophthalmic solution 0.09%.[1] FDA’s Orange Book identifies approved drug products, therapeutic-equivalence evaluations, patent information, and exclusivity information where applicable.[2]

The product’s commercial status should be analyzed separately from its original NDA approval. A product may be discontinued commercially without the NDA having been withdrawn for safety or efficacy reasons. Generic availability, current labeling, approved supplements, and listed patents require review of FDA records rather than reliance on pharmacy availability alone.

For investment or licensing decisions, the relevant regulatory questions are:

• Whether the NDA remains active.
• Whether approved ANDA products are therapeutically equivalent.
• Whether any patents remain listed.
• Whether a generic applicant has submitted a Paragraph IV certification.
• Whether FDA has approved any successor or reformulated bromfenac products.
• Whether the product is subject to current manufacturing or supply constraints.

What are the best commercial opportunities around BROMDAY excipients?

The opportunity ranking is:

Opportunity	Market potential	Technical difficulty	Strategic assessment
Low-cost generic 0.09% solution	Moderate	Low to moderate	Vulnerable to price competition
Preservative-free bromfenac	High	Moderate to high	Strongest formulation opportunity
Premium comfort formulation	Moderate	Moderate	Requires clinical or user-experience support
Bromfenac combination product	High	High	Requires formulation and regulatory development
Improved multidose bottle	Moderate	Moderate to high	Attractive licensing opportunity
Hospital or surgery-center pack	Moderate	Low to moderate	Can reduce waste and improve procurement economics

A low-cost generic can achieve regulatory approval but generally has limited pricing power. A preservative-free product has better potential for brand differentiation and payer negotiation, although packaging and sterility costs are higher.

Combination products are commercially attractive because cataract surgery often involves several postoperative drops. A bromfenac combination with an antibiotic, corticosteroid, or ocular-surface-supportive component could reduce administration burden. The formulation risk is substantial because of pH compatibility, precipitation, preservative interactions, chemical degradation, and regulatory requirements for each active ingredient.

Key Takeaways

• BROMDAY is a once-daily bromfenac sodium 0.09% ophthalmic solution approved for postoperative ocular inflammation and pain.
• Its excipient system includes BAK, borate buffering agents, edetate disodium, povidone, sodium sulfite, tyloxapol, sodium hydroxide, and water for injection.
• BAK enables conventional multidose packaging but creates a clear opportunity for preservative-free reformulation.
• Generic entry risk is high for a conventional bromfenac solution after the expiration of original exclusivity.
• The strongest new-product opportunity is a preservative-free bromfenac product using unit-dose or protected multidose delivery.
• Formulation patents are likely to provide more practical value than broad active-ingredient patents for a legacy bromfenac product.
• Licensing a validated formulation with a proprietary container system may offer the fastest route to commercial differentiation.
• BROMDAY, XIBROM, PROLENSA, and BROMSITE require separate patent, regulatory, and commercial analyses.

FAQs About BROMDAY Excipient and Formulation Opportunities

Can BROMDAY be reformulated without benzalkonium chloride?

Yes. A developer can pursue a preservative-free formulation, but it must replace BAK with a packaging and sterility strategy that controls microbial contamination throughout the labeled in-use period.

Is tyloxapol essential to bromfenac ophthalmic performance?

Not necessarily. Tyloxapol supports wetting and formulation uniformity, but a competing product could use another surfactant or excipient system if it meets stability, tolerability, and performance requirements.

Does a generic BROMDAY product need the same inactive ingredients?

No. FDA-approved generic ophthalmic products may use different inactive ingredients when the formulation is acceptable under the applicable regulatory pathway and does not create safety or performance concerns.[3]

Could a bromfenac product with lower BAK concentration obtain premium pricing?

Potentially. The commercial case would depend on demonstrated ocular-surface benefits, stability, preservative effectiveness, packaging cost, and reimbursement positioning.

Is a bromfenac-corticosteroid combination commercially attractive?

Yes, because it could reduce postoperative drop burden. The main barriers are chemical compatibility, preservative strategy, dose uniformity, clinical development, and competition from existing fixed-dose or co-packaged products.

References

1. U.S. Food and Drug Administration. (2009). BROMDAY (bromfenac sodium ophthalmic solution) 0.09% prescribing information.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (2020). ANDAs for certain highly purified synthetic peptides: Guidance for industry.
4. U.S. Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary: Ophthalmic preparations and sterile products.
5. U.S. Food and Drug Administration. (2015). In vitro release testing and in vitro permeation testing studies for ophthalmic ointments: Guidance for industry.